{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:23Z","timestamp":1793650523114,"version":"4.5.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32163-y","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:13:11Z","timestamp":1766621591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["JAK-1 inhibitors in the management of atopic dermatitis in patients over 65 years old: a descriptive cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiayue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Robles-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Canzi Almada","family":"de Souza Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica Ferris","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo G.","family":"Ducati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0950-3731","authenticated-orcid":false,"given":"Hermenio","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"32163_CR1","doi-asserted-by":"publisher","first-page":"e0258219","DOI":"10.1371\/journal.pone.0258219","volume":"16","author":"LN Chan","year":"2021","unstructured":"Chan, L. N. et al. The epidemiology of atopic dermatitis in older adults: A population-based study in the united Kingdom. PloS One. 16, e0258219 (2021).","journal-title":"PloS One"},{"key":"32163_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.mcna.2019.08.009","volume":"104","author":"JI Silverberg","year":"2020","unstructured":"Silverberg, J. I. Atopic dermatitis in adults. Med. Clin. North. Am. 104, 157\u2013176 (2020).","journal-title":"Med. Clin. North. Am."},{"key":"32163_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench, Z. C. et al. Atopic dermatitis in America study: A Cross-Sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J. Invest. Dermatol. 139, 583\u2013590 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"32163_CR4","doi-asserted-by":"publisher","first-page":"e0292987","DOI":"10.1371\/journal.pone.0292987","volume":"18","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q., Yang, D., Xiong, C. & Li, X. Atopic dermatitis and cognitive dysfunction in middle-aged and older adults: A systematic review and meta-analysis. PLOS ONE. 18, e0292987 (2023).","journal-title":"PLOS ONE"},{"key":"32163_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.anai.2023.01.020","volume":"130","author":"D Mikhaylov","year":"2023","unstructured":"Mikhaylov, D., Ungar, B., Renert-Yuval, Y. & Guttman-Yassky, E. Oral Janus kinase inhibitors for atopic dermatitis. Ann. Allergy Asthma Immunol. Off Publ Am. Coll. Allergy Asthma Immunol. 130, 577\u2013592 (2023).","journal-title":"Ann. Allergy Asthma Immunol. Off Publ Am. Coll. Allergy Asthma Immunol."},{"key":"32163_CR6","doi-asserted-by":"publisher","unstructured":"Vardanyan, R. Chapter 4\u20133-Substituted and 1,3-Disubstituted Piperidines. in Piperidine-Based Drug Discovery (ed. Vardanyan, R.) 127\u2013146 (Elsevier, 2017). https:\/\/doi.org\/10.1016\/B978-0-12-805157-3.00004-1","DOI":"10.1016\/B978-0-12-805157-3.00004-1"},{"key":"32163_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/jpm13030384","volume":"13","author":"M Tampa","year":"2023","unstructured":"Tampa, M., Mitran, C. I., Mitran, M. I. & Georgescu, S. R. A new horizon for atopic dermatitis treatments: JAK inhibitors. J. Pers. Med. 13, 384 (2023).","journal-title":"J. Pers. Med."},{"key":"32163_CR8","doi-asserted-by":"publisher","unstructured":"Kim, Y., Seo, G., Koopman, J. J. E. & Yee, J. Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Clin. Exp. Allergy 55(9), 755\u2013772. https:\/\/doi.org\/10.1111\/cea.70125 (2025).","DOI":"10.1111\/cea.70125"},{"key":"32163_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00403-025-04278-9","volume":"317","author":"L Potestio","year":"2025","unstructured":"Potestio, L. et al. Efficacy and safety of JAK inhibitors in patients aged\u2009>\u200960 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study\u2014IL AD (Italian landscape atopic Dermatitis). Arch. Dermatol. Res. 317, 777 (2025).","journal-title":"Arch. Dermatol. Res."},{"key":"32163_CR10","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I. et al. 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. Br. J. Dermatol. 188, ljad162.047 (2023).","DOI":"10.1093\/bjd\/ljad162.047"},{"key":"32163_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/1744666X.2024.2301967","volume":"20","author":"M Napolitano","year":"2024","unstructured":"Napolitano, M., Potestio, L., Nocerino, M. & Patruno, C. Considerations for managing elderly patients with atopic dermatitis. Expert Rev. Clin. Immunol. 20, 501\u2013511 (2024).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"32163_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","volume":"37","author":"S Rajasimhan","year":"2020","unstructured":"Rajasimhan, S., Pamuk, O. & Katz, J. D. Safety of Janus kinase inhibitors in older patients: A focus on the thromboembolic risk. Drugs Aging. 37, 551\u2013558 (2020).","journal-title":"Drugs Aging"},{"key":"32163_CR13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","volume":"156","author":"M Lam","year":"2020","unstructured":"Lam, M. et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: A systematic review. JAMA Dermatol. 156, 1240\u20131245 (2020).","journal-title":"JAMA Dermatol."},{"key":"32163_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","volume":"37","author":"R Tanei","year":"2020","unstructured":"Tanei, R. Atopic dermatitis in older adults: A review of treatment options. Drugs Aging. 37, 149\u2013160 (2020).","journal-title":"Drugs Aging"},{"key":"32163_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser, D. M. et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr. Med. Res. Opin. 36, 367\u2013376 (2020).","journal-title":"Curr. Med. Res. Opin."},{"key":"32163_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson, E. et al. Validation of the atopic dermatitis control tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 19, 15 (2019).","journal-title":"BMC Dermatol."},{"key":"32163_CR17","doi-asserted-by":"publisher","unstructured":"Ireland, P. A., Verheyden, M., Jansson, N., Sebaratnam, D. & Sullivan, J. Infection risk with JAK inhibitors in dermatoses: a meta-analysis. Int. J. Dermatol. 64(1), 24\u201336. https:\/\/doi.org\/10.1111\/ijd.17501 (2025).","DOI":"10.1111\/ijd.17501"},{"key":"32163_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/cea.13784","volume":"51","author":"S de Lusignan","year":"2021","unstructured":"de Lusignan, S. et al. The epidemiology of eczema in children and adults in england: A population-based study using primary care data. Clin. Exp. Allergy. 51, 471\u2013482 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"32163_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu, D. K. et al. Atopic dermatitis (eczema) guidelines: 2023 American academy of Allergy, asthma and immunology\/American college of Allergy, asthma and immunology joint task force on practice parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations. Ann. Allergy Asthma Immunol. 132, 274\u2013312 (2024).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"32163_CR20","unstructured":"EMA recommends measures to minimise risk of serious side effects. with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency (EMA). (2022). https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders"},{"key":"32163_CR21","unstructured":"Commissioner, O. of the. Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. FDA (2024). https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"key":"32163_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N Engl. J. Med."},{"key":"32163_CR23","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaad.2022.02.051","volume":"87","author":"SA Sreekantaswamy","year":"2022","unstructured":"Sreekantaswamy, S. A., Tully, J., Edelman, L. S., Supiano, M. A. & Butler, D. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis. J. Am. Acad. Dermatol. 87, 1174\u20131176 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"32163_CR24","doi-asserted-by":"publisher","first-page":"2245510","DOI":"10.1080\/09546634.2023.2245510","volume":"34","author":"F Piscazzi","year":"2023","unstructured":"Piscazzi, F. et al. Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J. Dermatol. Treat. 34, 2245510 (2023).","journal-title":"J. Dermatol. Treat."},{"key":"32163_CR25","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.19507","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo, L. et al. Effectiveness and safety of Upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study. J. Eur. Acad. Dermatol. Venereol. 38, e152\u2013e154 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"32163_CR26","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky, E. et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397, 2151\u20132168 (2021).","journal-title":"Lancet"},{"key":"32163_CR27","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich, K. et al. Safety and efficacy of Upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 397, 2169\u20132181 (2021).","journal-title":"Lancet Lond. Engl."},{"key":"32163_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/bjd\/ljad229","volume":"189","author":"C Ertus","year":"2023","unstructured":"Ertus, C. et al. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br. J. Dermatol. 189, 368\u2013380 (2023).","journal-title":"Br. J. Dermatol."},{"key":"32163_CR29","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu, A. W. L. et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J. Allergy Clin. Immunol. 152, 1470\u20131492 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32163_CR30","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester, G. R. et al. Safety profile of Upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 9, e002735 (2023).","journal-title":"RMD Open."},{"key":"32163_CR31","unstructured":"Ireland, P. A., Verheyden, M., Jansson, N., Sebaratnam, D. & Sullivan, J. Infection risk with JAK inhibitors in dermatoses: a meta-analysis. Int J. Dermatol na."},{"key":"32163_CR32","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves, C., Penedones, A., Mendes, D. & Batel Marques, F. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur. J. Clin. Pharmacol. 78, 1923\u20131933 (2022).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"32163_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/12034754231211805","volume":"28","author":"N Tarafdar","year":"2024","unstructured":"Tarafdar, N. et al. The rate of infections with Janus kinase inhibitor treatment for atopic dermatitis: A systematic review and Meta-Analysis. J. Cutan. Med. Surg. 28, 83\u201385 (2024).","journal-title":"J. Cutan. Med. Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32163-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:35:36Z","timestamp":1768836936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32163-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32163"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32163-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HL has received consulting fees, attended advisory boards, and participated in clinical trials for the following: Aslam Pharm, AbbVie (Abbott), Amgen, AstraZeneca, Bausch health, Bristol-Myers-Squibb, Celgene, Dermira, Eli Lilly, GSK, Incyte, Janssen, La Roche-Posay, Leo Pharmaceutics, Merck Sharp & Dohme, Moonlake, Novartis, Pediapharma, Pfizer, RAPT, Regeneron, Sanofi, Takeda, and UBS. He has been an investigator in an AbbVie-funded clinical trial. All other coauthors possess no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Retrospective data were de-identified to ensure confidentiality, and verbal informed consent was obtained for any participant interactions. No experimental interventions were administered, and all treatments followed standard clinical care guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"2312"}}